| Date | Form | Description | Docs | XBRL | Pages |
| 06/14/12 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
|
46 |
| 03/16/12 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
|
44 |
| 01/30/12 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
94 |
| 01/26/12 | 5 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 01/18/12 | CT ORDER | Confidential treatment order |
|
1 | |
| 11/30/11 | 10-Q/A | Quarterly report pursuant to sections 13 or 15(d) |
|
36 | |
| 11/03/11 | 8-K | Current report filing |
|
3 | |
| 10/31/11 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/14/11 | 10-Q/A | Quarterly report pursuant to sections 13 or 15(d) |
|
|
3 |
| 09/23/11 | DEF 14A | Definitive proxy statements |
|
22 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...